Allergy Therapeutics
Allergy Therapeutics, a leading specialist in allergy immunotherapy, is headquartered in the United Kingdom and operates extensively across Europe and North America. Founded in 2003, the company has established itself as a pioneer in the development of innovative allergy treatments, focusing on both the diagnosis and management of allergic conditions. The firm’s core offerings include a range of allergy vaccines and immunotherapy products, distinguished by their unique formulations and patient-centric approach. Allergy Therapeutics is committed to advancing the field of allergy treatment, evidenced by its robust pipeline and significant clinical milestones. With a strong market position, the company continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by allergies.
DitchCarbon Score
How does Allergy Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergy Therapeutics's score of 37 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergy Therapeutics's reported carbon emissions
In 2023, Allergy Therapeutics reported total carbon emissions of approximately 4,291,000 kg CO2e. This figure includes Scope 1 emissions of about 431,000 kg CO2e, Scope 2 emissions of around 1,901,000 kg CO2e, and Scope 3 emissions totalling approximately 1,959,000 kg CO2e. Comparatively, in 2022, the company recorded total emissions of about 4,040,000 kg CO2e, with Scope 1 at approximately 437,000 kg CO2e, Scope 2 at around 1,742,000 kg CO2e, and Scope 3 at about 1,861,000 kg CO2e. This indicates a slight increase in total emissions year-on-year. In 2021, Allergy Therapeutics had total emissions of approximately 3,017,000 kg CO2e, with Scope 1 emissions of about 25,000 kg CO2e, Scope 2 emissions of around 1,305,000 kg CO2e, and Scope 3 emissions of approximately 614,000 kg CO2e. Despite these figures, there are currently no disclosed reduction targets or climate pledges from Allergy Therapeutics, indicating a potential area for improvement in their climate commitments. The company has not provided emissions data for 2020, which limits the ability to assess long-term trends comprehensively. Overall, Allergy Therapeutics is actively disclosing its emissions across all three scopes, but further commitments to reduction targets would enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 25,000 | 000,000 | 000,000 |
| Scope 2 | 2,257,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 614,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergy Therapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
